---
title: '2024 update: European consensus statement on gene therapy for spinal muscular
  atrophy'
date: '2024-06-15'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38878702/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240616180959&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: Spinal muscular atrophy (SMA) is one of the most common genetic diseases
  and was, until recently, a leading genetic cause of infant mortality. Three disease-modifying
  treatments have dramatically changed the disease trajectories and outcome for severely
  affected infants (SMA type 1), especially when initiated in the presymptomatic phase.
  One of these treatments is the adeno-associated viral vector 9 (AAV9) based gene
  therapy onasemnogene abeparvovec (Zolgensma®), which is delivered ...
disable_comments: true
---
Spinal muscular atrophy (SMA) is one of the most common genetic diseases and was, until recently, a leading genetic cause of infant mortality. Three disease-modifying treatments have dramatically changed the disease trajectories and outcome for severely affected infants (SMA type 1), especially when initiated in the presymptomatic phase. One of these treatments is the adeno-associated viral vector 9 (AAV9) based gene therapy onasemnogene abeparvovec (Zolgensma®), which is delivered ...